Glenmark Pharmaceuticals Board to Consider Interim Dividend; Q1FY26 Profit Falls 86%

Drug maker Glenmark Pharmaceuticals on Monday, September 22, 2025, informed that its board of directors will meet on Friday, September 26, 2025, to consider and approve the payment of an interim dividend, if any, on the company’s equity shares for FY26. The record date for the interim dividend, if declared, has been fixed as Tuesday, September 30, 2025.

First Quarter Financial Performance

Glenmark Pharmaceuticals reported a sharp 86.2% year-on-year (YoY) decline in net profit for the first quarter ending June 30, 2025, at ₹46.8 crore, down from ₹340.2 crore in Q1FY25. Despite the drop in profit, revenue increased marginally by 0.6% to ₹3,264 crore from ₹3,244 crore in the same quarter last year.

At the operating level, EBITDA declined 1.4% to ₹580 crore compared with ₹588.2 crore YoY. EBITDA margin for the quarter fell slightly to 17.7% from 18.1% in Q1FY25.

Performance By Geography

In India, sales from Glenmark’s formulation business stood at ₹1,239.9 crore in Q1FY26, compared with ₹1,196.2 crore a year earlier, reflecting a 3.7% YoY growth.

In North America, the business registered revenue of ₹778 crore for the quarter, up from ₹714.6 crore in Q4FY25, marking an 8.9% quarter-on-quarter (QoQ) increase. The growth was primarily driven by share gains in injectable product launches and partnered products.

Revenue from emerging markets, including RCIS, LATAM, MEA, and APAC, was ₹572.1 crore in Q1FY26, compared with ₹570.8 crore in the year-ago period, a 0.2% YoY increase. The company continues to anticipate double-digit growth on a constant currency basis.

Interim Dividend Consideration

The board meeting scheduled for September 26 will decide on the payment of an interim dividend. If approved, shareholders holding the stock as of the record date, September 30, will be eligible for the payout. The company has not indicated the dividend amount yet.

Read More: Shukra Pharmaceuticals Signs Strategic Distribution Agreement

Conclusion

Glenmark Pharmaceuticals’ Q1FY26 results reflect the impact of cost pressures and market challenges, resulting in a steep decline in net profit despite modest revenue growth. The board’s interim dividend decision will be closely watched by investors for signals on capital allocation and confidence in the business outlook across domestic and international markets.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.